x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Base to Base Biotech

The Base to Base Biotech podcast is a weekly look at what"s happening in the world of biotech, with interviews with biotech leaders around the world.Whether it"s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.

health & fitness medicine

All Episodes

63:28

Base to Base biotech podcast 56: GRIN genes and...

Base to Base Biotech ·

2026/04/24

This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic.Times:02:54 Immunic24:04 Neurvati Neurosciences/GRIN TherapeuticsGRIN TherapeuticsGRIN Therapeutics Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringing hope to patients and caregivers.In 2024, GRIN Therapeutics reported promising topline data from a phase

en

62:37

Base to Base biotech podcast 55: Beating transplant...

Base to Base Biotech ·

2026/04/17

This week, our conversations are with Steve Perrin, president and CSO of Eledon Pharmaceuticals, and Jason Bock, CEO and co-founder of CTMC.Times:03:18 CTMC35:46 Eledon PharmaceuticalsCTMCCTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change in real time without charge ups and allowing for better control as a company develops their research process. With all of the resources in one circular supply chain

en

40:43

Base to Base biotech podcast 54: Parkinson’s disease...

Base to Base Biotech ·

2026/04/10

This week, because April 11 is World Parkinson’s Day, we chat with Dieter Willbold, CSO of Priavoid, and Antje Willuweit, director preclinical development of Priavoid, and Karsten Eastman, CEO and co-founder of Sethera Therapeutics, about the company’s work on peptides.Times:02:52 Sethera Therapeutics22:35 PriavoidPriavoidPriavoid, a company advancing novel disease-modifying approaches for neurodegenerative disorders, recently presented preclinical proof-of-concept data for its candidate PRI-101 in

en

60:43

Base to Base biotech podcast 53: Diagnosing autism...

Base to Base Biotech ·

2026/04/03

On this week’s episode, as April 2 is World Autism Day, we have a conversation with Manish Arora, CEO of LinusBio, on its test that can rule out if someone has autism, and we talk to Thomas Kledal, CEO of Synklino, about improving kidney transplantation outcomes through better cytomegalovirus (CMV) prevention.Times:03:18 LinusBio35:43 SynklinoLinusBioLinusBio has expanded access to its ClearStrand ASD test, the first non-invasive biochemical tool to rule out autism spectrum disorder (ASD), for

en

64:36

Base to Base biotech podcast 52: Ketamine for...

Base to Base Biotech ·

2026/03/27

On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine and treatment-resistant depression, and with Krishna Polu, CEO, president and co-founder of new kidney health biotech company R1 Therapeutics.Times:03:57 HMNC Brain Health29:47 R1 TherapeuticsHMNC Brain HealthHMNC Brain Health is a Munich-based clinical-stage biopharma company developing personalised treatments for depression. It has a phase 2 programme using oral, non-dissociative

en

63:51

Base to Base biotech podcast 51: Ovarian cancer, blue...

Base to Base Biotech ·

2026/03/20

On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma, a company making progress in the battle with brittle bone disease.Times:03:36 Amorphical26:26 CureLab

en

71:50

Base to Base biotech podcast 50: Drugs for kidney...

Base to Base Biotech ·

2026/03/13

As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was yesterday, we’ve been able to squeeze them both in. The conversations this week are with Hansa Biopharma CEO Renée Aguiar-Lucander, about imlifidase for kidney transplant patients; Kyron.bio CEO Emilia McLaughlin, about glycosylation; and hydrogel-based drug delivery solutions company AmacaThera’s CEO, Mike Cooke.Times:03:56 Kyron.bio19:14 AmacaThera43:01 Hansa BiopharmaHansa BiopharmaHansa

en

51:32

Base to Base biotech podcast 49: Gene therapy for...

Base to Base Biotech ·

2026/03/06

This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics.Times:03:34 Purespring24:11 Panakeia TechnologiesPurespring TherapeuticsPurespring is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.The

en

52:47

Base to Base biotech podcast 48: GPCRs and beating...

Base to Base Biotech ·

2026/02/27

The conversations on this week’s podcast are with CEO of Merz Therapeutics, Stefan König, about a variety of neurodegenerative conditions and a botulinum neurotoxin, and with CEO of Kainova Therapeutics, Sean MacDonald, about – among other things – G-protein coupled receptors, or GPCRs.Times:03:21 Merz Therapeutics30:34 Kainova TherapeuticsKainova TherapeuticsKainova Therapeutics is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada. The company develops drug candidates

en

61:01

Base to Base biotech podcast 47: Accurate prostate...

Base to Base Biotech ·

2026/02/20

The conversations on this week’s podcast focus on a rapid and accurate prostate cancer diagnostic test, with Valley Diagnostics’ CEO Dave Taylor; and on gene therapy for retinal disease, with Lance Baldo, CEO of Beacon Therapeutics.Times:03:12 Beacon Therapeutics27:38 Valley DiagnosticsValley DiagnosticsValley Diagnostics is a Welsh company developing next‑generation lateral flow diagnostic tests designed for early detection of human and animal diseases.Their approach uses patented biomarkers to

en

48:02

Base to Base biotech podcast 46: Endometriosis and...

Base to Base Biotech ·

2026/02/13

The conversations on this week’s podcast are with Vibhor Gupta, director and founder of Pangaea Data, and endogene.bio CEO María Teresa Pérez Zaballos.Times:03:09 Pangaea Data23:43 endogene.bioEndogene.bioendogene.bio is a precision medicine company based in France developing a non-invasive diagnostic for endometriosis. The company’s aim is to apply precision medicine to female health.The company was formed in 2022 by Maria Teresa Perez Zaballos and Madeleine Moscatelli. Its innovations include a

en

45:23

Base to Base biotech podcast 45: Chronic pain,...

Base to Base Biotech ·

2026/02/06

This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained Therapeutics.Times:03:47 Affibody23:28 Sustained TherapeuticsSustained TherapeuticsA spin-out from the University of British Columbia in Canada, Sustained Therapeutics utilises a proprietary polymer gel technology to develop locally injected, long-acting medications. The platform is designed to release active pharmaceutical ingredients in a controlled manner over several weeks, aiming

en

47:04

Base to Base biotech podcast 44: Treating breast...

Base to Base Biotech ·

2026/01/30

This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative breast cancer. We also have a conversation with Erik Manting, CEO of immunotherapy company Mendus, and Janet Hoogstraate, CEO of the CDMO helping them, North X Biologics.Times:03:56 Pan Cancer T20:23 Mendus/NorthX BiologicsMendusMendus is a Swedish–Dutch immuno-oncology company developing cell-based therapies aimed at stopping cancers from coming back rather than treating only the initial tumour

en

50:27

Base to Base biotech podcast 43: Natural killer cell...

Base to Base Biotech ·

2026/01/23

This week, we have a conversation with Lisa Guerrettaz, executive director, Pharmacology and Translational Science at Artiva Biotherapeutics; and Avacta Therapeutics’ CEO Christina Coughlin.Times:04:12 Artiva Biotherapeutics21:30 Avacta TherapeuticsArtiva BiotherapeuticsArtiva Biotherapeutics is a clinical‑stage cell therapy company developing off‑the‑shelf (allogeneic) natural killer (NK) cell therapies for autoimmune diseases and cancer. Headquartered in San Diego and founded in 2019, the company

en

76:16

Base to Base biotech podcast 42: Treating blood...

Base to Base Biotech ·

2026/01/16

This week, three interviews, and five guests. We have conversations with Ulrik Tirsted Zeuthen, CEO, and Katarina Cantell, founder/CSO of Adalyon; Nisit Khandelwal, co-founder/CEO, Cycuria Therapeutics; and Craig Ritchie, founder/CEO of Scottish Brain Sciences and Deborah O’Neil, CEO/CSO of NovaBiotics as well as chair of the Life Sciences board of Opportunity Northeast, which runs ONE BioHub, and BioAberdeen.Times:02:38 Adalyon32:44 Cycuria Therapeutics53:43 Scottish Blood Services/One

en

53:30

Base to Base biotech podcast 41: Eyes, mitochondria...

Base to Base Biotech ·

2026/01/09

This week, we’re talking about eye treatments with Oculis CEO, Riad Sherif, we have a conversation about mitochondria, with the CEO of Vandria, Klaus Dugi, and there’s also a short discussion about GoCo Health Innovation City in Gothenburg, Sweden, with Moa Dicksdotter, Partnership and Ecosystem.Times:02:35 Vandria20:03 GoCo Health Innovation City25:54 OculisLooking to the eyesOculis is a Swiss ophthalmology company developing topical and biologic treatments for retinal disease and neuro‑ophthalmic

en

69:32

Base to Base biotech podcast 40: Anchored...

Base to Base Biotech ·

2025/12/19

This week, we’re talking about skin and wounds, with Ned Swanson, president and chief medical officer at PolarityBio, and Nikolai Sopko, chief operating officer, chief scientific officer and director at PolarityBio; and we discuss anchored immunotherapy with Howard Kaufman, CEO of Ankyra Therapeutics.04:03 Ankyra Therapeutics34:31 PolarityBioAnchored immunotherapiesAnkyra Therapeutics, based in Cambridge, Massachusetts, develops anchored immunotherapies that tether cytokines at the injection site to

en

66:20

Base to Base biotech podcast 39: Gene therapy for eye...

Base to Base Biotech ·

2025/12/12

This week, we have conversations with Jakob Andersson, vice president of engineering at Anaphora and founder and chairman of GAIA; Coave Therapeutics’ CEO Rodolphe Clerval; and MOBILion Systems’ CEO, Melissa Sherman.Times:03:13 Coave Therapeutics 24:43 GAIA Conference 36:55 MOBILion SystemsGenetic medicine for ophthalmologyCoave Therapeutics is a Paris‑based biotechnology company focused on developing genetic medicines using its ALIGATER platform. The company has pioneered ligand‑conjugated AAV

en

79:02

Base to Base biotech podcast 38: Obesity, life...

Base to Base Biotech ·

2025/12/05

This week, we have conversations with Sjanna Bosma, international relations officer at Health Holland; Mark Bagnall, CEO of Phenomix; and PDS Biotechnology CEO Frank Bedu-Addo.04:17 Phenomix 32:53 Health Holland 44:02 PDS BiotechnologyPhenomix takes on obesityPhenomix Sciences is a biotechnology company focused on precision obesity medicine. The firm has developed the MyPhenome test, a saliva‑based assay that uses machine‑learning algorithms and genetic risk scores to classify obesity phenotypes and

en

64:59

Base to Base biotech podcast 37: Life Sciences in...

Base to Base Biotech ·

2025/11/28

This week, we have conversations with Jérôme Van Biervliet, chair of the board of Flanders life sciences body Biovia and managing director at VIB; Sylvain Sachot, partner at Asabys Partners; and Jonas Béal, head of science strategy, R&D, at Owkin.03:32 Owkin 27:42 Biovia/VIB 38:06 Asabys PartnersBiovia/VIBBiovia has emerged as a new health innovation cluster in the Belgian region of Flanders, created through the merger of flanders.bio and MEDVIA.The organisation brings together more than 450

en

56 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown